Welcome to our dedicated page for Promis Neuroscie news (Ticker: PMN), a resource for investors and traders seeking the latest updates and insights on Promis Neuroscie stock.
Promis Neurosciences (PMN) is a clinical-stage biotechnology company pioneering precision antibody therapies targeting toxic misfolded proteins in neurodegenerative diseases. This page provides investors and researchers with timely updates on PMN's scientific advancements, clinical trial progress, and strategic developments.
Access comprehensive coverage of material events including regulatory milestones, research publications, and partnership announcements. Our curated news collection helps stakeholders track PMN's progress in developing treatments for Alzheimer's, ALS, and related disorders through its proprietary ProMIS™ discovery platform.
Key updates include clinical trial phase transitions, intellectual property developments, and peer-reviewed data disclosures. Bookmark this page for direct access to verified press releases and objective analysis of PMN's position in the neurodegenerative therapeutics landscape.
ProMIS Neurosciences (Nasdaq: PMN) reported its Q1 2024 financial results and corporate updates. The company is progressing with its Phase 1a clinical trial of PMN310 for Alzheimer's disease (AD), expecting top-line data by mid-2024. The trial evaluates safety, tolerability, and pharmacokinetics in healthy volunteers. ProMIS also plans a Phase 1b study in H2 2024. Recent publications support PMN310’s potential. In the ALS program, PMN267 showed promising preclinical data. ProMIS selected PMN400 as a lead vaccine candidate for synucleinopathies. Financially, ProMIS reported a cash decrease to $2.5M, R&D expenses of $2.1M, G&A expenses of $1.6M, and a net loss of $3.6M.
ProMIS Neurosciences Inc. published a study highlighting the selectivity of PMN310 in targeting toxic soluble aggregates in neurodegenerative diseases such as Alzheimer’s disease. The study shows PMN310's differentiation from other amyloid-beta-directed antibodies and its potential to improve efficacy and reduce risk associated with plaque-binding therapies. PMN310 is currently undergoing Phase 1a clinical studies, with promising initial data expected in mid-2024.
FAQ
What is the current stock price of Promis Neuroscie (PMN)?
What is the market cap of Promis Neuroscie (PMN)?
